Digital Desk, Mumbai. Ransomware attacks and IP and data theft are top cyber security concerns for pharma companies in India. This information has been given in a new report on Thursday. According to a Deloitte India-Data Security Council of India (DSCI) report, the pandemic and the increasing number of targeted attacks have prompted some pharma companies to double their cyber security investments.
Gaurav Shukla, Partner and Leader, Cyber at Deloitte India, said, “To be able to enhance this digital vision and build trust globally, the pharma sector must recognize cyber security as a key lever that drives data, operational Working towards enhancing security around technology technologies (OT) and supply chain. This ability to harness cyber security for business and digital transformation can help pharma organizations transition from a leader to a trusted leader, Shukla said. For major pharma companies, cyber security investments have increased by a minimum of 25 to 30 percent between 2019 and 2021.
The pandemic and the increasing number of targeted attacks have prompted some pharma companies to double their cyber security investments in the past 18 months. Additionally, 70 per cent of major pharma companies have focused on a zero-trust approach, with the need for a clear roadmap over the next two years, around network, data and access, as noted in the report.
eKalam CEO Karan Chadha and DSCI CEO, Ram Vedashree said, Production Linked Incentive (PLI) schemes and government support will encourage more specialized manufacturers and research-led organizations. The focus on adopting cyber security and effectively managing cyber risks will enable business transformation and establish market leaders in this field.